急性心肌梗死直接介入治疗后无复流现象形成因素分析

目的:探讨急性心肌梗死直接介入治疗后发生无复流现象的有关预测因素。方法:分析急性心肌梗死直接介入治疗后发生无复流患者67例。正常血流对照组70例,2组间临床资料及冠状动脉造影结果进行比较。结果:无复流组PCI前缺血时间较长[(5.9±3.6)vs(4.3±2.7),P<0.05],血栓负荷更重(83.5%vs67.1%,P<0.05),多支病变例数较多(76%vs54%,P<0.05),造影后心肌梗死溶栓试验(TIMI)血流常为0级或1级(90%vs64%,P<0.05),供应罪犯血管的侧支循环较少(10%vs20%,P<0.05)。结论:急性心肌梗死患者缺血时间长、多支血管病变、造影时TIMI血流0或1级、侧支循环较少者直接PCI后易发生无复流。     

急性ST段抬高型心肌梗死患者球囊后扩张相关性无复流的危险因素分析

目的]探究急性ST段抬高型心肌梗死(STEMI)患者行急诊经皮冠状动脉介入治疗(PCI)球囊后扩张相关性无复流的危险因素及其对预后的影响。 [方法]收集发病12 h内行急诊PCI术并进行球囊后扩张的STEMI患者共147例,根据TIMI血流分级分为正常血流组和无复流组。比较两组患者的基本临床资料、造影特征、术后疗效及术后1年内主要不良心血管事件(MACE)发生情况。对年龄、症状至PCI时间、罪犯病变长度、支架植入数量、血栓负荷进行回归分析,探究STEMI患者球囊后扩张相关性无复流的危险因素。并对无复流及术后1年主要不良心血管事件发生进行相关性分析,探究危险因素对预后的影响。 [结果]共有16例患者发生了球囊后扩张相关性无复流,无复流发生率为10.88%。单变量分析结果提示,年龄、症状至PCI时间、罪犯病变长度、支架植入数量、血栓负荷与急诊PCI术中发生球囊后扩张相关性无复流有关(P＜0.05)。多变量Logistic回归模型结果显示症状至PCI时间延长(OR:0.95,95%CI:0.92～0.99)、罪犯病变长度增加(OR:0.96,95%CI:0.93～0.99)、血栓负荷重(OR:0.14,95%CI:0.03～0.71)可作为球囊后扩张相关性无复流的独立危险因素。 [结论]症状至PCI时间延长、罪犯病变长度增加、血栓负荷重与球囊后扩张相关性无复流发生呈正相关,是球囊后扩张相关性无复流的独立危险因素。球囊后扩张相关性无复流发生率与术后1年再发心绞痛的发生率呈正相关。     

血栓抽吸导管在急性心肌梗死补救性经皮冠状动脉介入治疗中的应用

急性ST段抬高型心肌梗死(STEAMI)患者直接经皮冠状动脉介入术(PCI)应用血栓抽吸导管可显著改善减少"无复流"发生率,可明显改善血流,改善心肌灌注,不增加主要心脏不良事件的发生率,但对于STEAMI溶栓失败行补救PCI这部分患者应用血栓抽吸导管的研究很少,本文通过应用血栓抽吸导管辅助急诊补救性PCI治疗STEAMI,观察其对无复流现象的治疗效果及临床心血管事件的影响.     

首次急性ST段抬高型心肌梗死患者行直接经皮冠状动脉介入术中发生无复流合并心动过缓的危险因素

目的:探讨首次急性ST段抬高型心肌梗死(STEMI)患者,行直接经皮冠状动脉介入术(PPCI)中发生无复流合并心动过缓的特点及其危险因素。方法:选取2007年1月值2010年10月,安贞医院连续收入的首次急性STEMI并行PPCI的患者448例。根据术中梗死相关动脉前向心肌梗死溶栓试验(TIMI)血流分为:无复流组合并心动过缓20例和对照组428例。血管造影无复流被定义为:PPCI术中的TIMI血流分级0~2级。术中发生心动过缓定义为:术前心率≥60次/min,术中心率持续性或一过性60次/min。比较两组患者的基本临床资料、造影结果和手术相关资料的差异,分析首次急性STEMI患者PPCI术中发生无复流合并心动过缓的危险因素。结果:PPCI术中无复流组合并心动过缓患者20例,对照组428例,无复流合并心动过缓发生率为4.5%。研究共纳入33个指标,通过单变量分析发现,两组患者的罪犯血管完全闭塞、罪犯血管是前降支、罪犯血管是右冠状动脉、年龄、WBC、中性粒细胞百分比和HGB等参数间差异有统计学意义(P0.05);多变量Logistic回归模型认为,罪犯血管完全闭塞(OR=5.615,95%CI:1.266~24.911)和罪犯血管是右冠状动脉(OR=3.082,95%CI:1.176~8.078)可作为预测PPCI术中无复流合并心动过缓发生的危险因素。结论:罪犯血管完全闭塞和罪犯血管是右冠状动脉可作为预测首次急性STEMI患者PPCI术中发生无复流合并心动过缓的危险因素。     

血栓抽吸导管在冠脉介入治疗中对血栓病变TIMI血流的影响

目的:探讨血栓抽吸导管在经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)中对于血栓病变TIMI血流的影响。方法:对我院1年来急性冠脉综合征(ACS)冠状动脉造影(CAG)显示靶病变相关血管(target-related artery,TRA)血栓负荷的患者48(男35,女13)例,年龄(58±8)岁,随机分成试验组(血栓抽吸+PCI,n=25)与对照组(直接PCI,n=23)。收集所有病例的临床和CAG资料,对比两组患者PCI术中相关血管心肌梗死溶栓试验(thrombolysis in myocardial infarction,TIMI)血流情况。结果:试验组患者PCI术中无复流及慢血流发生率明显低于对照组(0%vs.17%,P0.05),两组患者PCI术后TIMIⅢ级血流无显著差异。结论:对于冠脉有血栓负荷病变进行血栓抽吸可以明显改善ACS患者IRA远端的前向血流,降低无复流现象的发生。     

急性ST段抬高心肌梗死行急诊经皮冠状动脉介入术无复流影响因素探讨

目的:探讨急性ST段抬高性心肌梗死(STEMI)患者,行经皮冠状动脉介入术(PCI)时无复流现象的发生率及其相关危险因素。方法:选择本院2010年8月至2013年3月之间,STEMI行急诊PCI术的患者458例,分成无复流(慢血流)组及血流良好组,观察一般临床基线,冠状动脉造影血管病变特点等资料之间的差异。结果:63例(13.8%)患者于PCI时出现了无复流/慢血流现象。两组在性别、年龄、族别、出现症状至PCI时间,既往是否存在吸烟史、高血压史、血脂异常等高危因素以及靶血管部位、血管长度及直径等,差异均无统计学意义(P0.05),而在既往存在心肌梗死病史,糖尿病患者中,无复流/慢血流较血流正常组是增高的。在术前心肌梗死溶栓分级(TIMI)血流≤1级的AMI患者以及靶病变PCI中存在血栓负荷者出现无复流/慢血流组较血流正常组高,两组之间存在差异(P0.05)。结论:STEMI急诊PCI术后无复流现象的出现与既往存在心肌梗死、糖尿病病史,术前TIMI血流≤1的AMI患者以及靶病变PCI中存在血栓负荷者可能有关。     

血栓抽吸联合重组人尿激酶原对急性心肌梗死急诊PCI术后慢血流或无复流的影响

目的:探讨血栓抽吸联合重组人尿激酶原对急性ST段抬高型心肌梗死(STEMI)高血栓负荷患者经急诊冠状动脉介入术(PCI)治疗后发生慢血流或无复流现象的影响。方法:回顾性分析2015-01-2018-08于河北省人民医院心脏中心行急诊PCI治疗的高血栓负荷STEMI患者279例,其中80例经血栓抽吸导管行血栓抽吸(血栓抽吸组),62例通过指引导管冠脉内应用重组人尿激酶原(冠脉溶栓组),65例行血栓抽吸后通过血栓抽吸导管靶血管内应用重组人尿激酶原(联合治疗组),72例直接PCI治疗(直接PCI组)。观察4组患者慢血流或无复流发生情况,应用单因素分析方法筛选与慢血流或无复流相关的临床指标,进一步行多因素logistic回归分析急诊PCI后发生慢血流或无复流的独立危险因素。结果:4组患者慢血流或无复流现象发生率均差异有统计学意义,联合治疗组慢血流或无复流的发生率低于另外3组(均P0.05);多因素logistic回归分析显示,再灌注时间(OR=2.986,95%CI:2.160～4.129,P0.001)、BMI(OR=1.698,95%CI:1.416～2.036,P0.001)及直接PCI(OR=7.255,95%CI:2.492～21.123,P0.001)是STEMI患者急诊PCI术后出现慢血流或无复流现象的独立危险因素,血栓抽吸联合重组人尿激酶原治疗(OR=0.224,95%CI:0.061～0.829,P=0.025)是慢血流或无复流的保护性因素。结论:血栓抽吸联合重组人尿激酶原治疗可降低STEMI高血栓负荷患者急诊PCI术后慢血流或无复流的发生率。     

急性STEMI患者急诊PCI术中无复流影响因素分析

目的探讨急性ST段抬高心肌梗死(STEAMI)患者行急诊PCI术中发生无复流的危险因素。方法连续选择因STEAMI住院符合急诊PCI治疗的患者88例,根据是否发生无复流分为正常血流组(n=73)和无复流组(n=15)。采用逐步筛选法选取自变量,多元logistic回归分析STEAMI患者急诊PCI后发生无复流的影响因素。结果 STEAMI患者行急诊PCI后无复流发生率为17.0%。无复流组与正常血流组患者间入院收缩压、合并2型糖尿病比例、肌钙蛋白T峰值、发病-再灌注时间、球囊扩张次数和靶血管置入数量比较,差异有统计学意义(P0.05)。多因素logistic回归分析显示入院收缩压100 mmHg(OR=1.019,95%CI:1.006～1.032)、合并2型糖尿病(OR=3.016,95%CI:1.984～3.245)、肌钙蛋白T峰值(OR=1.664,95%CI:1.242～1.845)、发病-再灌注时间(OR=2.988,95%CI:1.545～3.345)、球囊扩张次数(OR=1.864,95%CI:1.545～3.345),是急诊PCI术后无复流发生的独立危险因素(P0.05)。结论 STEAMI患者行急诊PCI后无复流发生与入院SBP100 mmHg、合并糖尿病、球囊扩张次数及发病-再灌注时间具有相关性。     

急性心肌梗死患者PCI术中球囊扩张度与术后无复流的关系

目的研究急性心肌梗死患者经皮冠状动脉介入术(PCI)中球囊扩张度与术后无复流发生的相关性。方法将本院收治的94例急性心肌梗死患者作为研究对象,分为观察组和对照组各47例。两组术前均进行常规治疗(服用氯吡格雷300mg,阿司匹林300mg等),且急诊PCI证实病变血管远端完全闭塞。其中,对照组经小球囊和低强度扩张后,可部分恢复闭塞血管远端血流,之后行支架植入术;观察组经小球囊和低压力预扩张后,可部分恢复闭塞血管远端血流,接着通过大球囊及强度扩张后行支架植入术。比较两组患者临床基线资料(性别、年龄、体质量指数、糖尿病史、高血压史、吸烟史等)、病变血管部位(右冠状动脉、回旋支、前降支)、血管开通时间及无复流的发生情况。结果两组患者临床基线资料比较,均无统计学意义(均P0. 05)。两组患者病变血管部位和血管开通时间的比较,无统计学意义(均P0. 05)。观察组无复流发生率为19例(40. 43%),较对照组5例(10. 64%)显著升高,差异有统计学意义(P 0. 05)。结论经小球囊和低压力预扩张,部分恢复闭塞血管远端血流后,通过大球囊及高强度扩张后行支架植入术,会增加急性心肌梗死患者PCI后病变血管无复流的发生率,提示术中球囊扩张度与术后无复流的发生率密切相关。     

女性急性心肌梗死患者急诊冠状动脉介入术后无复流发生的危险因素分析

目的探讨女性急性心肌梗死患者在接受急诊PCI术后出现冠状动脉无复流的相关危险因素。方法选择在复旦大学附属中山医院因急性ST段抬高型心肌梗死(STEMI)接受急诊PCI的女性患者178例,其中无复流组40例(TIMI 0~2级),正常血流组138例(TIMI 3级)。比较2组患者临床特点、心脏超声、冠状动脉造影结果。结果无复流组术后LVEF明显低于正常血流组[(50.4±9.4)%vs(55.0±9.7)%,P=0.016],院内病死率明显高于正常血流组(12.5%vs 3.6%,P=0.032)。无复流组糖尿病、血管近段病变、多支病变和病变血管数明显高于正常血流组,术后收缩压水平明显低于正常血流组,差异有统计学意义(P<0.05)。多因素logistic回归分析显示,血管近段病变(OR=2.177,95%CI:1.025~4.622,P=0.043)和病变血管数(OR=1.750,95%CI:1.085~2.821,P=0.022)是急诊PCI术后无复流发生的独立相关因素。结论急性心肌梗死急诊PCI术后发生无复流患者的预后较差。血管近段病变、病变血管数可能是女性患者发生无复流的独立预测因素。     

急性ST段抬高心肌梗死患者急诊经皮冠状动脉介入治疗无复流现象相关因素分析

目的探讨急性ST段抬高心肌梗死（STEMI）患者急诊经皮冠状动脉介入治疗（PCI）中出现无复流的相关危险因素。方法选取发病在12h内的1059例STEMI患者给予急诊PCI,收集患者的临床、造影和介入治疗资料。PCI术后,根据心肌梗死溶栓（TIMI）分级和校正TIMI帧数将患者分为正常血流组和无复流组。比较两组患者的基本临床资料、造影结果和手术相关资料的差异,分析STEMI患者急诊PCI术中出现无复流的原因。结果急诊PCI术中无复流组患者118例。正常血流组941例,无复流发生率为11．14％。研究共纳入63个指标,通过单变量分析发现,年龄、症状至PCI时间、谷草转氨酶、氯吡格雷使用情况、干预病变数、狭窄程度及血栓负荷与急诊PCI术中发生无复流具有相关性（P〈0．05）。多变量Logistic回归模型认为,年龄（OR=1．04,95％CI：1．02—1．06）与血栓负荷（OR=1．72,95％CI：1．07～2．76）可作为预测急诊PCI术中无复流发生的独立危险因素。结论年龄与血栓负荷可作为预测急性STEMI患者急诊PCI术中发生无复流的独立危险因素,而糖尿病、高血压、高血脂、吸烟等冠心病的传统危险因素与无复流未见相关性。     

血小板分布宽度对急性心肌梗死冠状动脉介入治疗中无复流的预测价值

目的:研究血小板分布宽度(PDW)对ST段抬高型心肌梗死(STEMI)患者直接经皮冠状动脉介入治疗(PCI)中无复流的预测价值。方法:回顾性分析118例发病12h内接受直接PCI的STEMI连续病例,根据直接PCI术中无复流的发生情况分为无复流组(33例)和正常血流组(85例)。比较2组患者的临床资料、实验室检查结果以及直接PCI结果,应用受试者工作曲线(ROC曲线)分析入院时PDW对无复流发生的预测价值。结果:无复流组患者入院时PDW水平明显高于正常血流组[(16.7±2.3)%∶(15.1±2.2)%,P<0.01]。应用ROC曲线分析PDW对无复流的预测价值,曲线下面积0.726(95%可信区间0.608～0.844,P<0.01)。当截点值为16.45%时,入院时PDW对直接PCI术中无复流进行预测的敏感性和特异性分别为80.0%和72.4%。结论:STEMI患者入院时PDW水平是直接PCI术中发生无复流的预测因素,并具有较好的敏感性和特异性。     

Clinical and procedural predictors of no-reflow phenomenon after primary percutaneous coronary interventions: experience at a single center.

BACKGROUND: The aim of the study was to identify clinical factors, angiographic findings, and procedural features that predict no-reflow phenomenon (Thrombolysis In Myocardial Infarction (TIMI) flow grade < or =2) in patients with acute myocardial infarction (AMI) who undergo primary percutaneous coronary intervention (PCI). METHODS AND RESULTS: A series of 382 consecutive patients with AMI underwent primary PCI within 12 h of symptom onset. Patients with ischemic symptoms continuing for more than 12 h were also included. Clinical, angiographic and procedural data were collected for each subject. Ninety-three (24.3%) of the patients developed no-reflow phenomenon, and their findings were compared with those of the reflow group. Univariate analysis showed that advanced age (>60 years), delayed reperfusion (> or =4 h), low (< or =1) TIMI flow prior to PCI, cut-off type total occlusion, high thrombus burden on baseline angiography, long target lesion (>13.5 mm) and large vessel diameter all correlated with no-reflow (p<0.05 for all). Multiple logistic regression analysis identified that advanced age (odds ratio (OR) 1.04, p=0.001), delayed reperfusion (OR 1.4, p=0.0004), low TIMI flow before primary PCI (OR 1.1, p=0.0002), target lesion length (OR 5.1, p=0.0003) and high thrombus burden (OR 1.6, p=0.03) on angiography as independent predictors of no-reflow phenomenon. CONCLUSION: The occurrence of no-reflow phenomenon after primary PCI can be predicted using simple clinical, angiographic and procedural features. In this selected group of patients, adjunctive pharmacotherapy and/or distal protection device may be of value.     

Impact of atrial fibrillation on the no-flow phenomenon during primary percutaneous coronary intervention

Background Atrial fibrillation(AF)is reported to be associated with worse flow in patients with the treatment of coronary thrombolysis. However,few studies investigated the impact of atrial fibrillation on the noreflow phenomenon in ST-segment elevation myocardial infarction(STEIMI)patients undergoing primary percutaneous intervention(PCI). Methods 1163 STEMI patients undergoing primary PCI from Jan 2013 to Dec2019 were enrolled. Atrial fibrillation was diagnosed based on the electrocardiogram's findings. Patients with a TIMI flow rate less than 3 were considered to have no-reflow. Factors related to the no-reflow phenomenon was analyzed by the logistic regression analysis. Results 158 patients were in the AF group and 1005 patients were in the non-AF group. The AF group had a significantly higher occurrence of cardiogenic shock(11.4% vs. 5.6%,P0.001),and in-hospital mortality(9.5% vs. 3.1%,P0.001)than the non-AF group. The multivariate analysis showed that AF was an independent risk factor for the no-reflow phenomenon after primary PCI(OR:2.11,95% CI:1.27-3.88,P=0.014). Conclusions STEMI patients with AF would have higher in-hospital adverse events and no-reflow phenomenon than though without AF.[S Chin J Cardiol 2020;21(2):98-103]     

急诊心脏介入治疗中无复流现象预防措施的效果观察

目的 探讨ST段抬高型急性心肌梗死患者行急诊经皮冠脉介入治疗术(PCI)出现无复流现象的原因及预防措施.方法 选择ST段抬高型急性心肌梗死患者202例,无急诊PCI治疗禁忌证,随机分为3组,分别给予常规PCI治疗、血栓抽吸和冠脉内注入血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂后PCI等不同的治疗,监测患者PCI治疗后血浆脑钠肽前体(pro-BNP)和PCI术后冠脉造影TIMI血流分级,记录患者住院时间和28 d死亡率.结果 三组患者间发病至梗死相关血管开通时间、总平均住院时间、PCI治疗术后28d死亡率差异无统计学意义.常规PCI治疗组无复流现象的发生率高于血栓抽吸组和冠脉内注入血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂组,并且血浆pro-BNP明显高于后者.结论 心肌梗死患者PCI术后无复流的发生与冠脉内微血栓形成有关,通过血栓抽吸和冠脉内注入血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂的方法可以有效减少无复流的发生.     

超选择性冠脉内注射硝普钠对急性心肌梗死急诊冠状动脉介入治疗中无再流现象的作用

目的:评价超选择性冠状动脉内注射硝普钠对急性心肌梗死(AMI)患者急诊经皮冠状动脉介入(PCI)治疗中梗死相关动脉(IRA)无复流现象的作用。方法:选择AMI急诊PCI后再通的IRA存在无复流现象者43例。21例患者经血栓抽吸导管超选择性梗死相关冠状动脉内注射法,22例患者采用常规指引导管内注射方法。药物均采用硝普钠100μg,2 s内"弹丸式"快速注射完毕。10 min后复查冠状动脉造影,评定冠状动脉血流TIMI分级及校正TIMI帧数(cTFC)。结果:两组均可明显改善急诊PCI后的无再流现象,超选择组所有患者梗死相关血管IRA血流恢复TIMIⅢ级,cTFC帧数由用药前的(84±7)帧降至(26±6)帧,与常规组相比较差异有统计学意义(P0.01)。结论:超选择性IRA内快速注射硝普钠100μg能更有效地改善AMI急诊PCI中无再流现象。     

Application of intra-aortic balloon pumping on no-reflow phenomenon in primary PCI for STEMI

background To investigate the effect of intra-aortic balloon pumping (IABP) on no-reflow phenomenon in primary percutaneous coronary intervention (PCI) for ST-Elevation Myocardial Infarction (STEMI). Methods Clinical data of 22 acute myocardial infarction patients after PCI with angiographic no-reflow phenomenon were retrospectively analyzed between January 2006 and December 2009.12 patients underwent IABP, other 10 patients as control group. We observed difference of cardiac structure, brain natriuretic pe...     

Usefulness of adjunctive pulse infusion thrombolysis after failed aspiration for massive intracoronary thrombus

Slow/no-reflow phenomenon during emergent percutaneous coronary intervention in patients with ST-elevation myocardial infarction (STEMI) results in a poor prognosis. A high thrombus burden was an independent predictor of angiographic slow/no-reflow phenomenon. We experienced a case of a STEMI patient with massive intracoronary thrombus. In our case, a massive red thrombus was aspirated easily by adjunctive pulse infusion thrombolysis (PIT) after failed aspiration. Adjunctive pulse infusion thrombolysis after failed aspiration might be a useful strategy to prevent the slow/no-reflow phenomenon in STEMI patients with massive intracoronary thrombus.     

老年ST段抬高型急性心肌梗死患者急诊冠状动脉介入术后无复流的预测因素

目的 探讨老年ST段抬高型急性心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)后无复流的独立预测因素。 方法 入选668例STEMI并急诊成功行PCI的老年患者,分为无复流组和复流组,收集患者的临床、冠状动脉造影和PCI资料评价无复流,分析评价无复流的独立预测因素。 结果 668例老年患者中,发生无复流181例(27.1％)。多元Logistic回归分析结果显示,入院收缩压＜100 mm Hg(1 mm Hg=0.133 kPa)、侧支血流0～1级、PCI前血栓负荷评分≥4分和使用主动脉内气囊反搏是老年STEMI患者急诊PCI后无复流的独立预测因素。随着无复流独立因素数量增加,无复流发生率显著升高,分别具有0、1、2、3和4个独立预测因素时无复流发生率分别是10.0％(2/20)、13.7％ (32/233)、30.8％(85/276)、38.1％(37/97)和59.5％ (25/42),差异有统计学意义(x2 =25.796,P＜0.01)。 结论老年STEMI患者急诊PCI后无复流的独立预测因素为入院收缩压＜100 mm Hg、侧支血流分级0～1级、PCI前血栓评分≥4分和使用主动脉内气囊反搏。     

Usefulness of preprocedural N-terminal pro-brain natriuretic peptide in predicting angiographic no-reflow phenomenon during stent implantation in patients with ST-segment elevation acute myocardial infarction

The no-reflow phenomenon after primary percutaneous coronary intervention (PCI) is associated with larger infarct size, worse functional recovery, and higher incidence of complication after acute ST-elevation myocardial infarction (STEMI). The aim of this study was to assess the relation between preprocedural N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and angiographic no-reflow phenomenon. We measured preprocedural serum NT-pro-BNP level in 159 consecutive patients with acute STEMI (aged 63 +/- 12 years; 72% men) before PCI. Angiographic no-reflow after PCI was defined as Thrombolysis In Myocardial Infarction (TIMI) flow grade <3. Baseline characteristics, including time from chest pain onset, between the no-reflow (n = 67) and normal-reflow groups (n = 92) were similar. NT-pro-BNP was significantly higher in the no-reflow group than the normal reflow group (1,982 +/- 3,314 vs 415 +/- 632 pg/ml; p = 0.005). Also, high-sensitivity C-reactive protein, monocytes, and troponin-T were significantly higher in the no-reflow group than the normal-reflow group. In the no-reflow group, NT-pro-BNP was much higher in patients with TIMI flow grade 0 (n = 41; 2,290 +/- 3,495 pg/ml) than those with TIMI grade 1 or 2 (n = 26; 1,575 +/- 2,340 pg/ml), but without significant difference. The area under the receiver-operating characteristic curve for NT-pro-BNP was 0.78, and the optimal cut-off value identified using receiver-operating characteristic curve analysis was 500 pg/ml. At the standard cut-off value of >500 pg/ml, increased NT-pro-BNP showed a high probability of no-reflow phenomenon (odds ratio 4.42, 95% confidence interval 1.15 to 17.00, p = 0.028). In conclusion, preprocedural NT-pro-BNP may be a strong predictor of the development of no-reflow phenomenon after PCI in patients with acute STEMI.